Furthermore, several recent studies have demonstrated that high CXCL10 level is an indicator of positive response to immune checkpoint blockade (ICB) in melanoma, neuroblastoma, breast and urothelial cancers [45,46,47,48]. This evidence concerns the gene CXCL10 and neuroblastoma.